The Glucose Insulin in Stroke Trial (GIST)

Not Applicable

Completed

• Conditions: Cardiovascular diseases: Cerebrovascular disease; Circulatory System; Stroke

• Registration Number: ISRCTN31118803
• Lead Sponsor: HS R&D Regional Programme Register - Department of Health (UK)

Brief Summary

2003 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/12615981 2004 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/14671236 2004 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/14695867 2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17434094

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-01-23
• Study Completion: 2006-06-30
• Last Update Posted: 12 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 2500

Inclusion Criteria

All acute stroke patients (less than 24 hours onset) with cerebral infarction (CI) or primary intracerebral haemorrhage (PICH) and admission plasma glucose greater than 6.1 and less than 17 mMol/l.

Exclusion Criteria

1. Subarachnoid haemorrhage
2. Renal failure (urea 320 mMol/l or creatinine 3200 mMol/l)
3. Anaemia (Hb less than 9.0 g/dl)
4. Coma
5. Isolated posterior circulation syndromes with no physical disability
6. Pure language disorders
7. Established history of insulin dependent diabetes mellitus
8. Previous disabling stroke (Modified Rankin score 3)
9. Established diagnosis of dementia or abbreviated mental test score less than 7/10
10. Symptomatic cardiac failure - New York Heart Association (NYHA) Grade 3 or 4

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality at 12 weeks.

Secondary Outcome Measures

Name	Time	Method
Proportion of patients with a poor outcome (modified Rankin score 4 - 6) at 12 weeks between treatment groups.